Chi Ching Mak
Overview
Explore the profile of Chi Ching Mak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hudson A, Santora V, Petroski R, Almos T, Anderson G, Barido R, et al.
Bioorg Med Chem Lett
. 2020 Jun;
30(14):127214.
PMID: 32527538
A strategy to conformationally restrain a series of GlyT1 inhibitors identified potent analogs that exhibited slowly interconverting rotational isomers. Further studies to address this concern led to a series of...
2.
Tam B, Chiu K, Chung H, Bossard C, Nguyen J, Creger E, et al.
Cancer Lett
. 2019 Sep;
473:186-197.
PMID: 31560935
The Wnt/β-catenin signaling pathway is aberrantly activated in colorectal (CRC) and many other cancers, and novel strategies for effectively targeting it may be needed due to its complexity. In this...
3.
Santora V, Almos T, Barido R, Basinger J, Bellows C, Bookser B, et al.
J Med Chem
. 2018 Jun;
61(14):6018-6033.
PMID: 29886732
We report here the identification and optimization of a novel series of potent GlyT1 inhibitors. A ligand design campaign that utilized known GlyT1 inhibitors as starting points led to the...
4.
Mak C, Bampos N, Sanders J
Angew Chem Int Ed Engl
. 2018 May;
37(21):3020-3023.
PMID: 29711135
Rigid and flexible linkers are combined in the new dendrimer shown schematically in the picture, which contains nine metalloporphyrin units (Porph). The construction is such that the four "arms" of...
5.
Palanki M, Cao J, Chow C, Dneprovskaia E, Mak C, McPherson A, et al.
Expert Opin Drug Discov
. 2013 Mar;
4(1):33-49.
PMID: 23480335
Background: The synthesis of novel benzotriazine heterocycles was developed independently around the same time by Bischler, Bamberger and Arndt. Over the years, different groups have reported the synthesis of benzotriazine...
6.
Noronha G, Cao J, Chow C, Dneprovskaia E, Fine R, Hood J, et al.
Curr Top Med Chem
. 2008 Aug;
8(10):905-21.
PMID: 18673174
Chronic myelogenous leukemia (CML) is a hematological stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood...
7.
Geron I, Abrahamsson A, Barroga C, Kavalerchik E, Gotlib J, Hood J, et al.
Cancer Cell
. 2008 Apr;
13(4):321-30.
PMID: 18394555
Polycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized by mutant JAK2 (JAK2V617F) signaling, erythrocyte overproduction, and a propensity for thrombosis, progression to myelofibrosis, or acute leukemia....
8.
Wernig G, Kharas M, Okabe R, Moore S, Leeman D, Cullen D, et al.
Cancer Cell
. 2008 Apr;
13(4):311-20.
PMID: 18394554
We report that TG101348, a selective small-molecule inhibitor of JAK2 with an in vitro IC50 of approximately 3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced...
9.
Palanki M, Akiyama H, Campochiaro P, Cao J, Chow C, Dellamary L, et al.
J Med Chem
. 2008 Mar;
51(6):1546-59.
PMID: 18311895
Age-related macular degeneration (AMD) is one of the leading causes of loss of vision in the industrialized world. Attenuating the VEGF signal in the eye to treat AMD has been...
10.
Cao J, Fine R, Gritzen C, Hood J, Kang X, Klebansky B, et al.
Bioorg Med Chem Lett
. 2007 Sep;
17(21):5812-8.
PMID: 17827012
We describe the design, synthesis and structure-activity relationship studies in optimizing a series of benzotriazine compounds as potent inhibitors of both Abl and Abl-T315I enzymes. The design includes targeting of...